Max Hodak’s vision chip is now legal to implant in European eyes.
That sentence carries weight because it marks the first time a brain-computer interface designed to restore human sight has cleared regulatory approval in the EU—and because Hodak, the former president of Elon Musk’s Neuralink, is the one who made it happen. Science Corporation, the startup Hodak founded after leaving Neuralink, has just won EU approval to sell its vision-restoring neural implant to blind patients across Europe. The approval is a watershed moment for the neural interface industry, but it’s also a signal of something larger: the race to build profitable, revenue-generating brain chips is accelerating, and the first company to hit $100 million in annual revenue from neural implants will reshape what comes next.
- The Regulatory Milestone: Science Corporation has become the first brain-computer interface company to win EU approval for a vision-restoring neural implant, clearing the path for commercial implantation across all 27 member states.
- The Revenue Threshold: Hodak has identified $100 million in annual revenue as the inflection point at which neural interface infrastructure—manufacturing, insurance reimbursement, hospital networks—becomes self-sustaining and defensible.
- The Market Scale: Approximately 43 million people worldwide are blind or severely visually impaired, giving Science Corp a significantly larger addressable market than Neuralink’s motor-restoration focus, which targets an estimated 17 million people with spinal cord injuries.
Here’s what matters right now. Hodak told TechCrunch that “the thing that the space needs is a company making $100 million a year of revenue.” That’s not rhetoric. It’s a threshold statement. Once a neural interface company crosses into nine-figure annual revenue, the infrastructure—manufacturing, clinical support, regulatory pathways, insurance reimbursement—begins to calcify around that product. Science Corp’s EU approval puts it on a direct path to that milestone, which means the company’s vision chip isn’t just a medical device for blind patients. It’s a beachhead for an entire ecosystem of neural implants that Hodak and his team have been quietly planning. For readers tracking the privacy implications of brain-computer interfaces, this commercial acceleration makes the stakes considerably higher.
Science Corporation’s chip works by implanting a small electrode array directly into the visual cortex—the part of the brain that processes sight. Patients who are blind due to retinal degeneration or optic nerve damage can’t use their eyes to see, but their visual cortex often remains intact. The implant bypasses the damaged eye entirely, capturing images from an external camera and translating them into electrical signals that the brain can interpret as patterns of light and dark. Early trials showed that patients could recognize shapes, navigate rooms, and read large text. It’s not natural sight. It’s more like seeing through a low-resolution thermal camera. But for someone who has been blind for years, it’s transformative.
• A 2026 NIH-published analysis of BCI commercialization notes that Second Sight Medical Products first illuminated the regulatory pathway in 2011 with EU approval of the Argus II Retinal Prosthesis, establishing the foundational precedent that Science Corp’s approval now builds upon.
• Research published in PMC on global BCI governance identifies the EU’s Medical Device Regulation, the Artificial Intelligence Act, and the General Data Protection Regulation as the three overlapping frameworks that any neural implant company must satisfy to operate across European markets—a regulatory gauntlet that Science Corp has now cleared.
• The convergence of these three regulatory frameworks means EU-approved neural implants carry data governance obligations that extend well beyond device safety, covering how neural signal data is stored, processed, and shared.
How Does the EU Approval Change the Competitive Landscape?
The EU approval is significant because it clears the path for commercial implantation across 27 member states. Patients in Germany, France, Spain, and elsewhere can now receive the procedure, which means Science Corp can begin generating the revenue Hodak mentioned. But the approval also reveals something about the competitive landscape that Elon Musk’s Neuralink has been operating in. Hodak left Neuralink in 2021 and founded Science Corp in 2023. Neuralink itself has been moving toward human trials for a different kind of neural interface—one designed to restore motor control to paralyzed patients—but it hasn’t yet achieved the regulatory milestone that Science Corp just crossed. That’s a meaningful gap.
Hodak’s comment about the $100 million revenue threshold isn’t casual. It reflects a hard truth about medical device companies: they need scale to survive. A neural implant business operating at $10 or $20 million in annual revenue can’t sustain the clinical infrastructure, manufacturing quality control, and regulatory compliance that brain chips demand. But once you hit $100 million, you can hire the talent, build the facilities, and establish the relationships with hospitals and insurance companies that make the business durable. You also create a moat. Competitors have to match your manufacturing capability, your clinical track record, and your reimbursement relationships. That’s expensive and slow.
Why Does Insurance Coverage Determine Whether This Technology Reaches You?
For you as a potential patient or someone who cares about someone who is blind, this matters because it determines whether neural vision restoration becomes a realistic option or remains a rare, expensive novelty. If Science Corp reaches $100 million in revenue, insurance companies will begin covering the procedure. Hospitals will train surgeons to perform it. The cost per implant will drop. If the company stalls at $20 million, the procedure stays boutique—available only to wealthy patients who can pay out of pocket or participate in research trials. The relationship between medical device revenue and insurance coverage is not incidental—it is the mechanism by which experimental procedures become standard care. Understanding how insurance companies evaluate emerging medical claims is increasingly relevant as neural implant coverage decisions approach.
The broader pattern here echoes something familiar in big tech: the first mover to achieve profitability in a new category often becomes the category leader. Google dominated search because it got to scale first. Facebook dominated social because it reached critical mass before competitors. In neural interfaces, Science Corp is positioning itself as the first company to achieve sustainable revenue from a consumer-facing neural implant. That’s a different market than search or social, but the dynamics are similar. Once you’re generating $100 million a year from vision chips, you have the resources to develop the next product—a motor control interface, a cognitive enhancement tool, a communication device for locked-in patients. You also have the regulatory relationships and clinical infrastructure to move faster than competitors.
43 million – People worldwide who are blind or severely visually impaired, representing Science Corp’s primary addressable market
27 – EU member states now open to commercial implantation following regulatory clearance
$100M – Annual revenue threshold Hodak identifies as the inflection point for sustainable neural interface infrastructure
17 million – Estimated global population with spinal cord injury paralysis, the smaller market Neuralink’s motor-restoration focus targets
What Does Hodak’s Departure from Neuralink Actually Signal?
Hodak’s departure from Neuralink and his founding of Science Corp suggests a strategic divergence. Neuralink, under Musk’s direction, has focused on motor restoration—helping paralyzed patients regain control of their limbs through a brain-computer interface. That’s a smaller addressable market than blindness. Approximately 43 million people worldwide are blind or severely visually impaired. The number of people with paralysis from spinal cord injury is closer to 17 million. If Science Corp can capture even a small percentage of the blind population in developed markets, the revenue potential is substantial.
The EU approval also matters because it signals regulatory confidence in the safety and efficacy of the implant. The European Union’s approval process for medical devices is rigorous, and it’s separate from FDA approval in the United States. Science Corp will still need to pursue FDA clearance to sell in America, but the EU approval provides clinical evidence that regulators in another major market found credible. That accelerates the path to US approval and increases the likelihood that insurance companies will cover the procedure. The EU’s data protection framework also means that Science Corp’s neural signal data practices have already been scrutinized under some of the world’s most demanding privacy standards—a point worth noting given the sensitivity of data generated directly from brain activity. Readers interested in how EU data rights apply to emerging technologies may find the right to be forgotten framework increasingly relevant as neural implants generate persistent personal data.
Is the $100 Million Milestone Actually Within Reach?
What happens next is the real test. Science Corp needs to convert EU approval into actual implants in actual patients, and those patients need to report sustained benefit over months and years. Manufacturing needs to scale without quality failures. Clinical teams need to perform surgeries without complications. Insurance companies need to agree to reimburse. Any stumble in these areas could slow the path to $100 million in revenue. But if Science Corp executes, it becomes the first neural interface company to achieve sustainable profitability from a human-implanted brain chip. That’s the threshold that reshapes the industry. Watch for the first quarterly earnings report in 2027 that shows Science Corp approaching $20 million in annual revenue. That’s when you’ll know whether Hodak’s $100 million prediction is on track.
